Summary (255 words)
The endothelial isoform of nitric oxide synthase (eNOS) is a key determinant of vascular tone. eNOS, a Ca 2+ /camodulin-dependent enzyme, is also regulated by a variety of agonist-activated protein kinases, but the role and regulation of the protein phosphatase pathways involved in eNOS dephosphorylation are much less well understood. Treatment of endothelial cells with VEGF (vascular endothelial growth factor), a potent eNOS agonist, leads to the activation of calcineurin, a Ca 2+ /camodulin-dependent protein phosphatase. In these studies, we used a phosphorylation state-specific antibody to show that VEGF promotes dephosphorylation of eNOS at serine residue 116 in cultured endothelial cells. Cyclosporin A, an inhibitor of calcineurin, completely blocks VEGFinduced eNOS dephosphorylation; under identical conditions, cyclosporin A also inhibits VEGF-induced eNOS activation. VEGF-induced eNOS dephosphorylation shows an EC 50 of 2 ng/ml and is maximal 30 minutes after agonist addition. eNOS phosphorylation at serine 116 is completely blocked by the protein kinase C inhibitor calphostin, but is not blocked either by wortmannin (an inhibitor of phosphatidylinositide 3-kinase), nor by the MAP kinase pathway inhibitor U0126. A phosphorylation-deficient mutant of eNOS, in
Introduction
The endothelial isoform of nitric oxide synthase (eNOS) is a key determinant of vascular homeostasis (for review see (1) ). eNOS enzyme activity is closely controlled by diverse extracellular signals that also modulate myriad other regulatory pathways in endothelial cells. Nitric oxide synthesized by eNOS promotes the relaxation of vascular smooth muscle cells, leading to a reduction in blood pressure. eNOS is a Ca (7)); and serine 116 (2) . Of these phosphorylation sites, the regulation of eNOS serine 1179 has been most extensively characterized: protein kinase Akt ((3), (4)), the AMP-activated protein kinase (8) , and the cyclic AMP-dependent protein kinase (9), among others, have been shown to modify eNOS at this residue, thereby potentiating eNOS enzyme activity. The phosphorylation of threonine 497 appears to be modulated by the agonist bradykinin ((5), (7)), but the intracellular pathways involved in this response remain less well understood. Phosphorylation of eNOS at serine 116 has been observed in intact endothelial cells subjected to hemodynamic shear stress (2) , but the regulatory consequences of eNOS phosphorylation at this site are almost entirely unknown.
In these studies, we will show that the eNOS agonist vascular endothelial growth factor (VEGF) promotes eNOS activation associated with the dephosphorylation of eNOS at serine 116 in a pathway blocked by the phosphatase inhibitor cyclosporin A.
The principal molecular target of cyclosporin A is the Ca 2+ 4 principal side effect represents an important dose-limiting toxicity (12) . There is some evidence that cyclosporin A attenuates endothelium-dependent vasorelaxation (13, 14) , but a clear relationship between calcineurin action and eNOS regulation has not yet been clearly established. One agonist known to activate calcineurin in endothelial cells is vascular endothelial growth factor (VEGF) (15) , which is also one of the key activators of eNOS in the vessel wall.
VEGF treatment of endothelial cells leads to a transient increase in intracellular Ca 2+ (16) , as well as the activation of diverse protein tyrosine kinase and serine/threonine kinase pathways (17) . VEGF promotes the activation of eNOS by Ca 2+ /calmodulin, and also stimulates the protein kinase Akt, which directly phosphorylates eNOS on serine 1179 and increases enzyme activity ((3), (7)). Since VEGF also activates the phosphatase calcineurin in endothelial cells (15) , in the present studies we explored the hypothesis that VEGF modulates eNOS phosphorylation pathways involving calcineurin, and we have therefore Plasmids -The eNOS Ser116A mutant was constructed by standard PCR-based mutagenesis methods using cDNA encoding wild-type bovine eNOS (18) as template, with flanking primers at the EcoRI and BglII sites located in the upstream polylinker and the BglII sites in the middle of the eNOS coding sequence, respectively. Following amplification, purification, restriction digestion and molecular cloning of the PCRgenerated fragment containing the mutation, the nucleotide sequence of the amplified region of the cDNA was validated by dideoxynucleotide sequencing using standard techniques. For construction of the S116A mutant, the upstream primer pair was comprised of the forward primer 5'-CGCGAATTCGAAGGAGCCACCATGGGCAACTTGAAGAG- Dulbecco′s Modified Eagle's medium supplemented with fetal bovine serum (10%) as described (19) . Cells were plated onto gelatin-coated culture dishes, and studied prior to cell confluence between passage 5 and 9; cells were serum-starved overnight prior to experimental treatments. COS-7 cells were maintained in culture, transfected with various cDNA constructs using FuGENE6 as previously described (19), and studied 48 hours following transfection.
Immunoblot analysis and NOS activities assay -Cell lysates were prepared using a cell lysis buffer containing Nonidet P-40, and the degree of protein expression and phosphorylation were assessed as we previously described in detail (19) . eNOS activity in intact cultured cells was quantified as the formation of L-
arginine as described previously (19) .
Other methods -All experiments were performed at least three times. Mean values for individual experiments were expressed as mean ± S.E. Statistical differences were assessed by analysis of variance followed by t-test. A p value less than 0.05 was considered statistically significant. As can be seen in Figure 2 , cyclosporin also markedly reduced VEGF-induced phosphorylation of kinase Akt, and also attenuated VEGF-promoted ERK activation.
We next performed a more detailed pharmacological characterization of VEGFinduced eNOS dephosphorylation at serine 116. The time course of VEGF-induced eNOS dephosphorylation at serine 116 showed a maximum effect at 30 minutes and did not return to basal levels even one hour after adding VEGF. This response is considerably slower than seen with the VEGF-promoted phosphorylation of serine 1179, which has a maximal response at 5 minutes, and returns to basal levels by 30 min (Figure 3 ; see also ref. (16)).
The dose response to VEGF showed an EC 50 of 2 ng/ml ( Figure 3B ), consistent with the 8 EC 50 observed with other biological responses elicited by VEGF ( (20), (21)).
In order to more fully understand the consequences of eNOS phosphorylation at serine 116 on enzyme activity, we mutated serine 116 to alanine in the eNOS cDNA (to yield the plasmid S116A-eNOS), and transfected this construct into COS-7 cells.
Immunoblots probed with the serine 116-phospho-eNOS antiserum detected a band corresponding to eNOS in COS-7 cells transfected with wild-type eNOS, but not in cells transfected with the phosphorylation-deficient S116A eNOS mutant (Figure 4 ).
Immunoblot analysis revealed that the wild-type and S116A mutant constructs yielded a similar amount of total eNOS expression, with no substantive difference in the level of eNOS serine 1179 phosphorylation between the wild-type and S116A mutant eNOS We next sought to explore the protein kinase pathways that might be involved in the phosphorylation of eNOS on serine 116. The "kinase consensus sequence" around serine 116 suggests that this residue might represent a site for phosphorylation by ERK1/2 MAP kinases. However, the MAP kinase kinase inhibitor U1026 had no effect on eNOS serine 116 phosphorylation, under conditions in which ERK1/2 activation was completely blocked by this inhibitor treatment ( Figure 5A ). The phosphatidylinositide 3-kinase (PI3-kinase) inhibitor wortmannin similarly had no effect on eNOS serine 116 phosphorylation under conditions in which phosphorylation of the PI3-kinase downstream kinase Akt was completely blocked ( Figure 5A ). Of a wide range of kinase inhibitors, we found that the protein kinase C inhibitor calphostin was distinct in its ability to completely block phosphorylation of eNOS at serine 116, accompanied by a significant attenuation in phosphorylation at serine 1179 ( Figure 5B ). remains to be determined in enzymological studies of the purified enzyme.
It should be emphasized that the fact that cyclosporin inhibits VEGF-induced eNOS serine 116 dephosphorylation does not establish that calcineurin directly dephosphorylates eNOS, any more than the inhibitory effects of calphostin on serine 116 phosphorylation establish protein kinase C as the enzyme directly responsible for eNOS phosphorylation at this site. As shown in Figure 5 , we found that calphostin, a protein kinase C inhibitor, also blocks phosphorylation of eNOS at serine 1179, an observation more consistent with a role for protein kinase C in kinase Akt activation ( Figure 5B ) than with the hypothesis the protein kinase C itself directly modifies this eNOS residue. Thus, we may only interpret the effects of the protein kinase C inhibitor calphostin and the calcineurin inhibitor cyclosporin on phosphorylation of serine 116 as providing evidence that protein kinase Cand calcineurin-modulated pathways importantly influence eNOS phosphorylation at this residue. Indeed, the amino acid sequence surrounding serine 116 does not represent a particularly robust consensus sequence either for protein kinase C-induced phosphorylation or for calcineurin-promoted dephosphorylation. A broadly-based experimental approach will be required in order to identify the specific molecular targets that are modulated by protein kinase C and calcineurin in endothelial cells.
The major findings of this study are that VEGF, a key eNOS agonist, promotes the dephosphorylation of eNOS at serine 116; that this VEGF response is blocked by cyclosporin A; and that serine 116 phosphorylation is associated with eNOS inhibition. 
